文献速递泌尿男性生殖肿瘤

转移性激素敏感性前列腺癌化学激素治疗:III期随机试验E3805 CHAARTED长期生存分析

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
PubMed 文献 · J Clin Oncol · 2018-01-31

CHAARTED试验纳入790例转移性激素敏感性前列腺癌患者,随机接受ADT联合多西他赛(75 mg/m2,最多6周期)或ADT单药。

要点

  • ADT联合多西他赛显著延长高肿瘤负荷转移性激素敏感性前列腺癌患者的总生存期。
  • 低肿瘤负荷患者未从化学激素治疗中获得总生存获益。
  • 高肿瘤负荷定义为内脏转移和/或≥4处骨转移且至少1处位于脊柱和骨盆之外。

核心结论

  • 在高肿瘤负荷转移性激素敏感性前列腺癌患者中,化学激素治疗可延长总生存期;低肿瘤负荷患者未见总生存获益。

研究设计与样本

  • III期随机对照试验,纳入790例转移性激素敏感性前列腺癌患者,等比例随机分配至ADT联合多西他赛75 mg/m2最多6周期组或ADT单药组,主要终点为总生存期。

关键数值与推荐

  • 高肿瘤负荷定义为存在内脏转移和/或≥4处骨转移且至少1处位于脊柱和骨盆之外。

临床怎么用

  • 对高肿瘤负荷转移性激素敏感性前列腺癌患者,可考虑ADT联合多西他赛治疗;低肿瘤负荷患者不推荐该联合方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature follow-up and focus on tumor volume. Patients and Methods In this phase III study, 790 patients with metastatic hormone-sensitive prostate cancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/m2 for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the prospectively defined low- and high-volume disease subgroups were performed. High-volume disease was defined as presence of visceral metastases and/or ≥ four bone metastases with at least one outside of the vertebral column and pelvis. Results At a median follow-up of 53.7 months, the median OS was 57.6 months for the chemohormonal therapy arm versus 47.2 months for ADT alone (hazard ratio [HR], 0.72; 95% CI, 0.59 to 0.89; P = .0018). For patients with high-volume disease (n = 513), the median OS was 51.2 months with chemohormonal therapy versus 34.4 months with ADT alone (HR, 0.63; 95% CI, 0.50 to 0.79; P < .001). For those with low-volume disease (n = 277), no OS benefit was observed (HR, 1.04; 95% CI, 0.70 to 1.55; P = .86). Conclusion The clinical benefit from chemohormonal therapy in prolonging OS was confirmed for patients with high-volume disease; however, for patients with low-volume disease, no OS benefit was discerned.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018. PMID: 29384722. doi:10.1200/JCO.2017.75.3657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。